Evidence map›Paper›PMID 40463365›Full record

ArticleFrontiers in immunology2025

Single-cell transcriptomics reveals cellular dynamics and chemokine CXCL2-mediated smooth muscle cell proliferation in arterial repair.

Xingxiao Huang, Yan Ping, Qiuli Sun, Mingjun Yu, Chao Yang, Xiao Liu, Long Wang, Jinyu Huang

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xingxiao Huang *Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Yan Ping *Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Qiuli SunHangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Mingjun YuHangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Chao YangDepartment of Cardiology, Westlake Laboratory of Life Sciences and Biomedicine, Affiliated Hangzhou First People's Hospital, Westlake University School of Medicine, Hangzhou, China.
Xiao LiuDepartment of Cardiology, Westlake Laboratory of Life Sciences and Biomedicine, Affiliated Hangzhou First People's Hospital, Westlake University School of Medicine, Hangzhou, China.
Long WangDepartment of Cardiology, Westlake Laboratory of Life Sciences and Biomedicine, Affiliated Hangzhou First People's Hospital, Westlake University School of Medicine, Hangzhou, China.
Jinyu HuangHangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Percutaneous coronary intervention (PCI) remains the primary treatment for coronary artery disease (CAD), yet post-procedural arterial injury triggers cellular change and pathological inflammation, leading to thrombosis and restenosis. Recent studies have highlighted the chemokine CXCL2 play an important role in the immune response to tissue repair. However, the cellular mechanisms and the role of chemokine CXCL2 underlying arterial repair after PCI remain poorly understood. Methods: Single-cell RNA sequencing (scRNA-seq) was used to characterize the heterogeneity and gene expression profiles of cells in a femoral artery injury (FAI) model. Animal models of FAI and cellular experiments were used to validate the effects of CXCL2 on smooth muscle cell proliferation. Results: (1) Mesenchymal stem cells (MSCs), smooth muscle cells (SMCs), and macrophages play pivotal roles in arterial repair. And distinct subpopulations within these cell types were identified, each exhibiting unique functional characteristics and temporal dynamics during repair. (2) Notably, we identified an inflammatory SMC subpopulation (SMC2) that actively secretes chemokine CXCL2, which promotes SMC proliferation and mediates arterial remodeling after injury, suggesting its potential as a therapeutic target. Conclusions: This study provides a comprehensive cell atlas of the injured artery, offering valuable insights into the complex cellular interactions, signaling pathways and immune responses involved in orchestrating vascular repair. Our findings show chemokine CXCL2 as a key mediator of SMC proliferation and provide a roadmap for developing CXCL2-targeted therapies to improve vascular outcomes in PCI patients.

Indexed as

Chemokine CXCL2Femoral ArteryMuscle, Smooth, VascularMyocytes, Smooth MuscleTranscriptomeAnimalsCell ProliferationDisease Models, AnimalGene Expression ProfilingHumansMacrophagesMaleMesenchymal Stem CellsMiceMice, Inbred C57BLSingle-Cell AnalysisChemokine CXCL2arterial repaircellular dynamicsCXCL2single-cell transcriptomicssmooth muscle cell proliferation

Identifiers

PMID40463365
PMCPMC12129781

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.